fda warning letters glp-1 compounders october 2025 Compounded Semaglutide & Tirzepatide 2025: Safe Use Guide

FDA Issues 30 Warning Letters to Telehealth Companies Over GLP-1 Claims | FDA posted on the topic

20.93

★★★★☆4.8 (126)

National Hispanic Medical Association | After compounded GLP-1 drugs were banned, counterfeit versions continued to circulate — and still do today. Understanding the risks and

20.86

★★★★★4.9 (98)

Report: FDA must enforce rules on compounded GLP-1s

21.20

★★★★★5.0 (157)

September 15, 2025: Telehealth company must stop implying its compounded GLP -1 is FDA-approved, warns FDA – Partnership for Safe Medicines

22.42

★★★★★4.7 (84)

FDA is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified

26.69

★★★★★4.9 (203)

Today, the FDA established a “green list” import alert to help stop potentially dangerous GLP-1 active pharmaceutical ingredients from unverified foreign sources from entering the U.S. market. The agency will continue to

27.36

★★★★★5.0 (176)

Why the FDA Issued 30 Warning Letters to Telehealth Sites Marketing Compounded GLP-1s

21.04

★★★★★4.8 (132)